Jyong Biotech (MENS) Change in Accured Expenses (2024 - 2025)

Jyong Biotech (MENS) posted quarterly Change in Accured Expenses of $59000.0 for Q2 2025, up 43.9% quarter-over-quarter from $41000.0 in Q4 2024.

Jyong Biotech (MENS) Change in Accured Expenses (2024 - 2025) Analysis & Trends

Jyong Biotech's Change in Accured Expenses history runs 2 years deep, the most recent figure standing at $59000.0 for Q2 2025.

In Q2 2025, Change in Accured Expenses changed N/A year-over-year to $59000.0; the TTM figure through Jun 2025 stood at $59000.0 (changed N/A YoY), while the FY2025 annual figure was $10000.0, up 100.65% from the prior year.
Change in Accured Expenses for Q2 2025 stood at $59000.0, up from $41000.0 in the prior quarter.
The five-year high for Change in Accured Expenses was $59000.0 in Q2 2025, with the low at $41000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Accured Expenses (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	222.50 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	492.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	11.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	212.44 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	61.62 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	68.82 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Jyong Biotech	159.89 Mn	159.89 Mn	-	-

Download Data